United States - English - NLM (National Library of Medicine)

remedyrepack inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9) ]. the data on use of buprenorphine, the active ingredient in buprenorphine sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational studies have reported on congenital malformations among buprenorphine-exposed pregnancies, but

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9) ]. the data on use of buprenorphine, the active ingredient in buprenorphine sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational studies have reported on congenital malformations among buprenorphine-exposed pregnancies, but w

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - fentanyl citrate (micronized) 157.1 µg eqv. fentanyl - tablet - fentanyl citrate (micronized) 157.1 µg eqv. fentanyl 100 µg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - fentanyl citrate (micronized) 314.2 μg eqv. fentanyl - tablet - fentanyl citrate (micronized) 314.2 μg eqv. fentanyl 200 µg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - fentanyl citrate (micronized) 471.3 μg eqv. fentanyl - tablet - fentanyl citrate (micronized) 471.3 μg eqv. fentanyl 300 µg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - fentanyl citrate (micronized) 628.4 μg eqv. fentanyl - tablet - fentanyl citrate (micronized) 628.4 μg eqv. fentanyl 400 µg

Singapore - English - HSA (Health Sciences Authority)

a. menarini singapore pte. ltd. - fentanyl citrate (micronized) 942.6 μg eqv. fentanyl - tablet - fentanyl citrate (micronized) 942.6 μg eqv. fentanyl 600 µg

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - fentanyl - sublingual tablet - 67 microgram(s) - phenylpiperidine derivatives; fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - fentanyl - sublingual tablet - 133 microgram(s) - phenylpiperidine derivatives; fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - fentanyl - sublingual tablet - 267 microgram(s) - phenylpiperidine derivatives; fentanyl